Matteo Ruggeri

Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

Paolo Caraceni, Oliviero Riggio, Paolo Angeli et al. · The Lancet · 2018 · 514 citations · Full text

Medicine, Internal Medicine, Hepatology +9

Costs of Bloodstream Infections Caused by <i>Escherichia coli</i> and Influence of Extended-Spectrum-β-Lactamase Production and Inadequate Initial Antibiotic Therapy

Mario Tumbarello, Teresa Spanu, Rossella Di Bidino et al. · Antimicrobial Agents and Chemotherapy · 2010 · 223 citations · Full text

Life Sciences, Infectious Diseases, Pharmacoeconomics +13

Telemedicine as technoinnovation to tackle COVID-19: A bibliometric analysis

Carlo Drago, Andrea Gatto, Matteo Ruggeri · Technovation · 2021 · 80 citations · Full text

Law, Health Sciences, Infectious Diseases +7

Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study

Luisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci et al. · Journal of Crohn s and Colitis · 2018 · 75 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C

Calogero Cammà, Salvatore Petta, Giuseppe Cabibbo et al. · Journal of Hepatology · 2013 · 57 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +14